PMC:7172841 / 33769-33966
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T238 | 188-196 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T309 | 168-173 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T282 | 168-173 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T265 | 0-197 | Sentence | denotes | Six patients with immune dysregulation were treated with single intravenous infusion of 8 mg/kg of Tocilizumab (RoAcremra, Roche) based on the National Health Care off-label provision for COVID-19. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T98 | 18-38 | Phenotype | denotes | immune dysregulation | http://purl.obolibrary.org/obo/HP_0002958 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T942 | 18-24 | UBERON:0002405 | denotes | immune |
T943 | 25-38 | GO:0065007 | denotes | dysregulation |
T944 | 99-110 | DG_35 | denotes | Tocilizumab |
T945 | 188-196 | SP_7 | denotes | COVID-19 |
T31044 | 18-24 | UBERON:0002405;GO:0006955 | denotes | immune |
T46550 | 25-38 | GO:0006955 | denotes | dysregulation |
T8807 | 18-24 | UBERON:0002405 | denotes | immune |
T62677 | 25-38 | GO:0065007 | denotes | dysregulation |
T41838 | 99-110 | DG_35 | denotes | Tocilizumab |
T58306 | 188-196 | SP_7 | denotes | COVID-19 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1198 | 4-12 | Species | denotes | patients | Tax:9606 |
1199 | 99-110 | Chemical | denotes | Tocilizumab | MESH:C502936 |
1201 | 188-196 | Disease | denotes | COVID-19 | MESH:C000657245 |